Effect of 12 weeks' treatment with budesonide/formoterol single inhaler, budesonide plus formoterol separate inhalers or budesonide alone on clinic assessed pulmonary function, expressed as geometric means (baseline data in table 1)
| Efficacy variables | Single inhaler therapy | Separate inhaler therapy | Budesonide |
| Patients n | 123 | 115 | 124 |
| FEV1 L | |||
| Baseline value (CV %) | 2.28 (39) | 2.33 (35) | 2.24 (36) |
| Week 12 | 2.47* | 2.50** | 2.35 |
| (95% CI) | (2.40–2.55) | (2.43–2.58) | (2.28–2.43) |
| FVC L | |||
| Baseline value (CV %) | 3.30 (38) | 3.36 (31) | 3.24 (33) |
| Week 12 | 3.45 | 3.49 | 3.38 |
| (95% CI) | (3.37–3.54) | (3.40–3.58) | (3.29–3.47) |
FEV1: forced expiratory volume in one second
CV: coefficient of variation
CI: confidence interval
FVC: forced vital capacity
*: p<0.05 versus budesonide
**: p<0.01 versus budesonide (for ratio of geometric means), no significant difference (p>0.05) was seen for the pair-wise comparisons between the single inhaler and separate inhaler groups